Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.

Lawitz EJ, Membreno FE.

J Gastroenterol Hepatol. 2014 Aug;29(8):1574-81. doi: 10.1111/jgh.12632. Review.

PMID:
24852401
2.

[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].

Ben Yakov G, Montano D, Abu Freha N, Etzion O, Dizingof V, Mushkalo A, Shwarts D, Monitin S, Takchick A, Zilberman D, Sikuler E, Fich A.

Harefuah. 2016 May;155(5):272-5, 324, 323. Hebrew.

PMID:
27526553
3.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
4.

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.

Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, Galle PR, Alshuth U.

J Gastrointestin Liver Dis. 2016 Mar;25(1):15-24. doi: 10.15403/jgld.2014.1121.251.a2a.

5.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023.

6.

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.

Can J Gastroenterol. 2012 Apr;26(4):205-10. Review.

7.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
8.

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020.

PMID:
23542346
9.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators..

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X.

PMID:
23768747
10.

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Barritt AS 4th, Fried MW.

Gastroenterology. 2012 May;142(6):1314-1323.e1. doi: 10.1053/j.gastro.2012.02.013. Review.

11.

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

Pearlman BL.

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Review.

PMID:
22647717
12.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x.

13.

[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Makara M.

Orv Hetil. 2015 Mar 1;156(9):343-51. doi: 10.1556/OH.2015.30106. Review. Hungarian.

PMID:
25702254
14.

Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.

Corti G, Salomoni E, Baragli F.

Int J Infect Dis. 2014 Feb;19:85-6. doi: 10.1016/j.ijid.2013.09.002.

15.

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N.

Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006.

PMID:
24727022
16.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.

Hepatology. 2012 Aug;56(2):567-75. doi: 10.1002/hep.25865.

PMID:
22619063
17.

Hepatitis C therapy update.

Casey LC, Lee WM.

Curr Opin Gastroenterol. 2012 May;28(3):188-92. doi: 10.1097/MOG.0b013e3283528e1e. Review.

PMID:
22476156
18.

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.

Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP.

J Hepatol. 2014 Apr;60(4):748-56. doi: 10.1016/j.jhep.2013.12.013.

PMID:
24362076
19.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Review.

PMID:
22975763
20.

A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.

Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.

J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006.

PMID:
24477330
Items per page

Supplemental Content

Support Center